The center's research covers both basic medicine and translational medicine. Basic medical research is mainly through molecular biotechnology and animal disease models to investigate (1) the molecular mechanisms associated with tumor development, cancer metastasis, and drug resistance; (2) the signal transduction pathways and epigenetic regulation mechanisms in the process of stem cell differentiation, and (3) the adjuvant targeted therapies with more therapeutic effects, including immunotherapy.
With these basic researches, translational medicine attaches great importance to the identification of new tumor markers for diagnosis and the prediction of the tumor markers for early recurrence and anticancer target therapy. These achievements will accelerate the development of early cancer diagnosis and novel anticancer drugs and help to develop more effective targeted therapies, and through clinical trials and collaboration with physicians, set up a personalized medical treatment model. In addition, it will also contribute to the industry-academia collaboration, research, and development, supporting the development of domestic medical research and promoting the nation's biotech industry's overall capacity.
The center has long maintained close academic exchanges and collaboration with the University of Texas MD Anderson Cancer Center, with respect to liver cancer, breast cancer, lung cancer, colorectal cancer, cancer stem cells, and other studies, and has met with great success with an international competitive edge.